Figure 3
Chemotherapy can increase PID1 mRNA. (A–C) Medulloblastoma (D283MED, UW228) and glioblastoma (U87, LN229, LN18, D54) cell lines (4 × 105 cells/6-well) were treated for 24 hrs with vincristine (A: 50 ng/ml), etoposide (B: 5 µg/ml in D283, UW228, U87, LN229, LN18; 10 µg/ml in D54), or cisplatin (C: 5 µg/ml in D283, U87, LN229, LN18; 10 µg/ml in UW228-2 and D54). (D–F) UW228 cells were treated with increasing doses of vincristine (VCR, panel D), etoposide (ETOP, panel E) or cisplatin (CDDP, panel F) for 24 hrs. (G) UW228 cells were treated with 5 µg/ml cisplatin for the times indicated. (H) D283 medulloblastoma treated as in (F). In all panels, cells were collected at end of incubation, RNA extracted, and qRT-PCR for PID1 mRNA analyzed. Experiments were performed in triplicate up to three times. Shown are fold change in PID1 mRNA relative to GAPDH mRNA of chemotherapy-treated compared to vehicle-treated cells, normalized to 1.
